INNOVATIVE HEALTH PRACTICES
ID: BAA-GH-OAA-2024Type: Special Notice
Overview

Buyer

AGENCY FOR INTERNATIONAL DEVELOPMENTAGENCY FOR INTERNATIONAL DEVELOPMENT

NAICS

All Other Professional, Scientific, and Technical Services (541990)

PSC

SUPPORT- PROFESSIONAL: OTHER (R499)

Original Source

https://sam.gov/opp/ef467544c4ee4331b6fac3a72ccc0276/view
Timeline
    Description

    Special Notice: AGENCY FOR INTERNATIONAL DEVELOPMENT is seeking innovative health practices through a Broad Agency Announcement (BAA). The purpose is to co-create, co-design, co-invest, and collaborate on research and development interventions to reduce disease and mortality rates worldwide. Organizations and companies are invited to submit an Expression of Interest (EOI) to generate novel tools and approaches for improved health outcomes in low-and-middle-income countries (LIMIC).

    Point(s) of Contact
    SHARON D DAVIS
    (202) 916-2644
    SHDAVIS@USAID.GOV
    Files
    Title
    Posted
    BAA-GH-OAA-2024 Innovative Health Practices.pdf
    Lifecycle
    Title
    Type
    INNOVATIVE HEALTH PRACTICES
    Currently viewing
    Special Notice
    Similar Opportunities
    Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA), is soliciting proposals under the Broad Agency Announcement (BAA) BAA-23-100-SOL-00004 for advanced research and development of Medical Countermeasures (MCMs) aimed at addressing public health threats such as chemical, biological, radiological, and nuclear (CBRN) incidents, as well as emerging infectious diseases and pandemic influenza. The initiative seeks to foster public-private partnerships to enhance the development and responsiveness of life-saving MCMs, emphasizing the importance of technological maturity, regulatory compliance, and manufacturing standards in the evaluation process. This opportunity is critical for strengthening national health security and improving preparedness for future public health emergencies, with an open submission period running until September 25, 2028, at 4:30 PM Eastern Time. Interested parties can direct inquiries to BARDA-BAA@hhs.gov for further information.
    BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Office of Biomedical Advanced Research and Development Authority (BARDA), is soliciting proposals under the Easy Broad Agency Announcement (EZ-BAA) BAA-22-100-SOL-00003, which focuses on innovative medical countermeasures (MCMs) to enhance public health preparedness against various threats, including infectious diseases and chemical agents. The initiative invites submissions across multiple Areas of Interest (AOIs), including but not limited to vaccine innovations, diagnostic technologies, and therapeutic solutions for acute radiation syndrome and chemical threats. This opportunity is critical for advancing biomedical research and developing effective responses to health emergencies, with multiple awards anticipated based on scientific merit and funding availability. Interested parties must register on SAM.gov and submit their abstracts by specified deadlines, with key submission dates ranging from March 15, 2024, to May 31, 2024, depending on the AOI. For further inquiries, respondents can contact Aarati Singal or Lara Emmons at DRIVeAcquisitions@hhs.gov.
    2026 NIAID DMID Omnibus Broad Agency Announcement
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and specifically the National Institute of Allergy and Infectious Diseases (NIAID), is soliciting proposals for the 2026 DMID Omnibus Broad Agency Announcement (BAA) aimed at advancing research and development of medical countermeasures against antimicrobial-resistant pathogens and viruses with pandemic potential. The BAA encompasses two primary research areas: the development of therapeutics, vaccines, and diagnostics for antimicrobial-resistant bacterial and fungal pathogens, and the creation of direct-acting antivirals for viral families of pandemic potential. This initiative is critical for addressing public health challenges related to infectious diseases and enhancing biodefense capabilities. Proposals for Research Area 001 are due by February 21, 2025, while those for Research Area 002 are due by January 21, 2025. Interested parties can reach out to primary contact Swee L. Teo at teosl@niaid.nih.gov or 240-669-5173 for further information.
    Sources Sought/RFI Innovations in Malaria Vaccines and Biologics Development (IMVB)
    Active
    Agency For International Development
    The United States Agency for International Development (USAID) is seeking input through a Sources Sought/Request for Information (RFI) regarding Innovations in Malaria Vaccines and Biologics Development (IMVB). The primary objective is to gather insights from small businesses capable of supporting the development of malaria vaccines and monoclonal antibodies (mAbs) that effectively target the Plasmodium falciparum parasite, addressing critical challenges such as drug resistance and vaccine efficacy. This initiative is part of USAID's commitment to enhancing malaria health solutions through strategic partnerships and innovative research, with a projected budget of $25-50 million over a span of 5 to 10 years. Interested parties are encouraged to provide organizational capacity information and feedback on the technical design outlined in the DRAFT SECTION C attachment, and can reach out to the primary contact, IMVB, at imvb@usaid.gov or the secondary contact, Natalia Kornilova, at nkornilova@usaid.gov for further details.
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development - HT9425-23-S-SOC1
    Active
    Dept Of Defense
    Special Notice DEPT OF DEFENSE is seeking proposals for extramural biomedical research and development. This opportunity is issued by the DEFENSE HEALTH AGENCY (DHA) under the BROAD AGENCY ANNOUNCEMENT (BAA) HT9425-23-S-SOC1. The purpose of this BAA is to solicit research and development ideas to advance the state-of-the-art or increase knowledge in the field. The projects funded under this BAA should focus on basic and applied research rather than the development of specific systems or hardware solutions. The research and development funding is expected to benefit both military and civilian medical practice and knowledge. Interested parties must submit a pre-proposal through the electronic Biomedical Research Application Portal (eBRAP). If selected, the offeror will be invited to submit a full proposal or application through Grants.gov. The BAA is open for a 5-year period, from August 1, 2023, to July 31, 2028. The BAA with revised research areas of interest and General Submission Instructions can be found on Grants.gov using opportunity number HT9425-23-S-SOC1.
    FY25 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is soliciting proposals through the FY25 Broad Agency Announcement (BAA) aimed at advancing regulatory science and innovation. This opportunity invites organizations, particularly small businesses, to submit research and development proposals that address critical areas such as alternative drug development methods, advanced manufacturing technologies, and predictive toxicology, with a strong emphasis on including diverse populations in research. Proposals must be submitted by February 24, 2025, and will undergo a two-tier evaluation process, with the potential for multiple contracts awarded based on proposal quality and funding availability. Interested parties can contact Ian Weiss at Ian.Weiss@fda.hhs.gov or by phone at 301-796-5728 for further information.
    Energy Sector Self-Reliance BAA
    Active
    Agency For International Development
    The AGENCY FOR INTERNATIONAL DEVELOPMENT has issued a Combined Synopsis/Solicitation notice for the procurement of support services in the SUPPORT- PROFESSIONAL: ENGINEERING/TECHNICAL industry. The notice titled "Energy Sector Self-Reliance BAA" seeks opportunities to co-create, co-design, and co-invest in the research, development, piloting, and scaling of innovative and cost-effective interventions to support the advancement of self-reliant energy sectors in developing countries. The service/item being procured is aimed at addressing the diverse set of challenges faced by countries striving to achieve universal access to reliable, affordable, and sustainable energy services. The procurement is open to organizations, companies, government agencies, academic and research institutions, and investors. The goal is to engage with a wide range of implementing partners and service providers within the global energy sector to strengthen national and regional energy systems. Subsequent Addenda will provide further details on how to participate in this opportunity.
    BROAD AGENCY ANNOUNCEMENT (BAA) RESEARCH AND DEVELOPMENT IN SUPPORT OF THE JOINT PROGRAM EXECUTIVE OFFICE FOR CHEMICAL, BIOLOGICAL, RADIOLOGICAL AND NUCLEAR DEFENSE (JPEO-CBRND), JPM MEDICAL AND JPL EB
    Active
    Dept Of Defense
    Solicitation DEPT OF DEFENSE is seeking research and development services in support of the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB. The service being procured is for the identification of the best available science in the areas of research interest, including novel solutions and improved methods for developing medical countermeasures. The government is specifically interested in enabling technologies, life cycle bioinformatics, and improved logistics tracking. The procurement notice is available on SAM.gov and the JPEO-CBD website. Potential offerors are encouraged to communicate with the JPMO technical contacts for proposal ideas. For any questions or inquiries, contact usarmy.detrick.mcs.mbx.baa@mail.mil.
    NEEDIPEDIA BROAD AGENCY ANNOUNCEMENT - BAA
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Intelligence Agency (DIA), is issuing a Broad Agency Announcement (BAA) titled "NEEDIPEDIA BROAD AGENCY ANNOUNCEMENT - BAA" (HHM402-23-S-0001) to solicit innovative ideas from a diverse range of sources, including large and small businesses, academic institutions, and independent consultants. The objective is to enhance the agency's operational efficiency and effectiveness by leveraging cutting-edge technological capabilities and innovative solutions that align with its national and international mission requirements. This opportunity emphasizes the importance of research and development in the physical, engineering, and life sciences sectors, particularly in areas such as Artificial Intelligence and Machine Learning, as outlined in the associated white papers. Interested parties should direct inquiries to Tamara Yockey at tamara.yockey@dodiis.mil or call 703-735-6377, and submissions must adhere to the specified guidelines, including a two-page limit for white papers, with relevant updates and templates provided in the attached documents.
    FY24 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science Award Notice
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Food and Drug Administration (FDA), has announced the FY24 Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science. This opportunity aims to support innovative research projects that enhance regulatory science, with a focus on health, medical, and biotechnology advancements. The awarded contracts, totaling over $24 million, cover a range of critical topics including drug safety, gene therapy, and methodologies for assessing pediatric opioid exposure, reflecting the federal government's commitment to fostering research initiatives that improve healthcare delivery and regulatory processes. Interested parties can contact Ian Weiss at Ian.Weiss@fda.hhs.gov or by phone at 301-796-5728 for further information.